Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
major depressive disorder
Biotech
Neurocrine-Takeda antidepressant hits main mark in phase 2 trial
Neurocrine has nabbed a phase 2 trial win after its oral drug reduced depression severity among adults who haven’t benefited from prior therapies.
Gabrielle Masson
Apr 23, 2024 10:44am
FDA clears Otsuka, Click's prescription app for depression
Apr 3, 2024 1:53pm
Neuronetics TMS nets first-line OK for depression in adolescents
Mar 26, 2024 11:02am
Alto Neuroscience preps IPO to push CNS therapies through clinic
Jan 16, 2024 6:51am
Psychiatry biotech hopes to Transcend PTSD rivals with new data
Dec 5, 2023 5:45pm
J&J neuroscience drugs take spotlight with lofty revenue goals
Dec 5, 2023 3:38pm